Yıl: 2021 Cilt: 4 Sayı: 4 Sayfa Aralığı: 276 - 282 Metin Dili: İngilizce DOI: 10.30714/j-ebr.2021471922 İndeks Tarihi: 10-02-2022

Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients

Öz:
Aim: Thyroid cancers are the most commonly encountered endocrine system malignancies. The incidencecontinues to rise worldwide. Our aim in this study is to investigate the frequency and histopathologicalsubtypes of thyroid cancer in our clinic. Methods: The present study was conducted with 3614 patients who were followed up in our endocrinologyand general surgery clinic and operated with the diagnosis of multinodular and/or nodular goiter between 2015and 2021. The histopathological types and information of patients diagnosed with thyroid cancer were obtainedretrospectively from the pathology reports. Among the patients included in the study, a total of 570 peoplewho were reported to have thyroid cancer due to histopathology were included in the study. Results: The data of a total of 3614 biopsy reports were examined for the study. Among these patients, 570(421 females, 149 males) were operated and whose pathology reports were accessed were included in thestudy. The mean age of the patients was 49.12±10.4 years. As a result of the operations, malign postoperativetissue histopathology was 98.9% (n=564), and uncertain malignancy potential was reported to be 1.0% (n=6).In our study, the histopathological distribution of thyroid cancers was as follows; thyroid papillary cancer89.4% (n=510), follicular cancer 7.3% (n=42), medullary cancer 2.1% (n=12), and malignancy potentialuncertain 1.0% (n=6). Conclusion: The results of our study suggest that thyroid cancers are more common in women in our country,in parallel with the similar rates reported in the literature, with the increase worldwide.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1]Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017;24(5):332-36.
  • [2]Chmielik E, Rusinek D, OczkoWojciechowska M, et al. Heterogeneity of Thyroid Cancer. Pathobiology. 2018;85(1- 2):117-29.
  • [3]Salamanca-Fernández E, RodriguezBarranco M, Chang-Chan YL, et al. Thyroid Cancer Epidemiology in South Spain: a population-based time trend study. Endocrine. 2018; 62(2): 423-31.
  • [4]Sağlık İstatistikleri Yıllığı 2017, T.C. Sağlık Bakanlığı, https://sbsgm.saglik.gov.tr/TR,50773/saglik istatistikleri-yilligi-2017- yayinlanmistir.html (ET: 18.03.2019).
  • [5]SEER Cancer Stat Facts. Thyroid cancer. Bethesda, MD: National Cancer Institute, https://seer.cancer.gov/statfacts/ht ml/thyro.html (accessed 9 October 2020).
  • [6]Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;23:381(9871):1058-69.
  • [7]Şahin N, Üçer Ö. Malatya’da yapılan tiroidektomilerde tiroid kanseri sıklığı. Dicle Med J. 2013; 40 (4): 570-73.
  • [8]National Cancer Institute: Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/thyro. html (accessed April 25, 2017).
  • [9]Shi LL, DeSantis C, Jemal A, et al. Changes in thyroid cancer incidence, post-2009 American Thyroid Association guidelines. Laryngoscope. 2017;127(10):2437-41.
  • [10]Guth S, Theune U, Aberle J, et al. Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39(8):699-706.
  • [11]Rosai J, Albores Saavedra J, Asioli S, et al. WHO classification of tumours of endocrine organs, WHO/IARC classification of tumours (4th), vol 10. International Agent for Research on Cancer. World Health Organization, Lyon: 2017;81–91.
  • [12]Dedivitis RA, Matos LL, GuimarÃes AV, et al. Neck recurrence in papillary thyroid carcinoma. Rev Col Bras Cir. 2020;47:e20202545.
  • [13]Ito Y, Fukushima M, Kihara M, et al. Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. Endocr J. 2012;59 (6):457-64.
  • [14]Baloch ZB, LiVolsi VA. Thyroid and Parathyroid. In: Mills SE, Greenson JK, Hornick JL, Longacre TA, Reuter VE, editors. Sternberg’s Diagnostic Surgical Pathology. 6th ed. Philadelphia, USA: Wolters Kluwer Health. 2015; 539-97.
  • [15]Kilfoy BA, Devesa SS, Ward MH, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1092-100.
  • [16]Zanotti-Fregonara P, Hindié E, Faugeron I, et al. Update on the diagnosis and therapy of distant metastases of differentiated thyroid carcinoma. Minerva Endocrinol. 2008;33(4):313-27.
  • [17]Ceolin L, Duval MADS, Benini AF, et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer. 2019;26(9):499-18.
  • [18]Viola D, Elisei R. Management of Medullary Thyroid Cancer. Endocrinol Metab Clin North Am. 2019;48(1):285-301.
  • [19]Yassin Fel-Z. Diagnostic criteria of well differentiated thyroid tumor of uncertain malignant potential; a histomorphological and immunohistochemical appraisal. J Egypt Natl Canc Inst. 2015;27(2):59-67.
APA Ozkul O, ERGENÇ H, Ertürk Z, GOKOSMANOGLU F (2021). Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. , 276 - 282. 10.30714/j-ebr.2021471922
Chicago Ozkul Ozlem,ERGENÇ HASAN,Ertürk Zeynep,GOKOSMANOGLU FEYZI Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. (2021): 276 - 282. 10.30714/j-ebr.2021471922
MLA Ozkul Ozlem,ERGENÇ HASAN,Ertürk Zeynep,GOKOSMANOGLU FEYZI Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. , 2021, ss.276 - 282. 10.30714/j-ebr.2021471922
AMA Ozkul O,ERGENÇ H,Ertürk Z,GOKOSMANOGLU F Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. . 2021; 276 - 282. 10.30714/j-ebr.2021471922
Vancouver Ozkul O,ERGENÇ H,Ertürk Z,GOKOSMANOGLU F Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. . 2021; 276 - 282. 10.30714/j-ebr.2021471922
IEEE Ozkul O,ERGENÇ H,Ertürk Z,GOKOSMANOGLU F "Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients." , ss.276 - 282, 2021. 10.30714/j-ebr.2021471922
ISNAD Ozkul, Ozlem vd. "Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients". (2021), 276-282. https://doi.org/10.30714/j-ebr.2021471922
APA Ozkul O, ERGENÇ H, Ertürk Z, GOKOSMANOGLU F (2021). Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. Experimental Biomedical Research, 4(4), 276 - 282. 10.30714/j-ebr.2021471922
Chicago Ozkul Ozlem,ERGENÇ HASAN,Ertürk Zeynep,GOKOSMANOGLU FEYZI Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. Experimental Biomedical Research 4, no.4 (2021): 276 - 282. 10.30714/j-ebr.2021471922
MLA Ozkul Ozlem,ERGENÇ HASAN,Ertürk Zeynep,GOKOSMANOGLU FEYZI Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. Experimental Biomedical Research, vol.4, no.4, 2021, ss.276 - 282. 10.30714/j-ebr.2021471922
AMA Ozkul O,ERGENÇ H,Ertürk Z,GOKOSMANOGLU F Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. Experimental Biomedical Research. 2021; 4(4): 276 - 282. 10.30714/j-ebr.2021471922
Vancouver Ozkul O,ERGENÇ H,Ertürk Z,GOKOSMANOGLU F Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients. Experimental Biomedical Research. 2021; 4(4): 276 - 282. 10.30714/j-ebr.2021471922
IEEE Ozkul O,ERGENÇ H,Ertürk Z,GOKOSMANOGLU F "Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients." Experimental Biomedical Research, 4, ss.276 - 282, 2021. 10.30714/j-ebr.2021471922
ISNAD Ozkul, Ozlem vd. "Histopathological distribution of thyroid cancers: A retrospective analysis of 570 patients". Experimental Biomedical Research 4/4 (2021), 276-282. https://doi.org/10.30714/j-ebr.2021471922